⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OSTX News
OS Therapies Incorporated
OS Therapies Third Quarter 2026 Corporate Outlook Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K
sec.gov
OSTX
OS Therapies Appoints Dr. Craig Eagle to Board of Directors Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Provides U.S. Regulatory Update Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update Ready to Announce with Confidence?
newsfilecorp.com
OSTX